GEHC

Over the past six months, GEHC's stock experienced several notable events. On April 29, 2026, the stock declined 13% to a 52-week low due to a Q1 earnings miss, reduced profit guidance, unexpected inflation, and a supplier issue. On July 30, 2026, the stock was upgraded to "Buy" following robust 11% year-over-year orders growth and a record $23.9 billion backlog. On August 7, 2026, the company reported strong Q2 results with $5.3 billion revenue (5.7% year-over-year growth) and 11.1% orders surge. On September 8, 2026, the stock moved below its 50-day moving average, and on September 11, 2026, the 10-day moving average crossed bearishly below the 50-day. On October 5, 2026, GE HealthCare announced the acquisition of SOFIE Biosciences for $945 million to bolster its radiopharma business. On October 7, 2026, the company announced its Q3 2026 financial results release for October 28, 2026. On October 8, 2026, GEHC closed at $63.89, reflecting a 15% loss over the preceding 12 months.